Select Vaccines signs agreement to develop Hep C test
Thursday, 25 March, 2004
Select Vaccines (ASX: SLT) has signed a materials transfer agreement (MTA) with a multinational biotechnology company to access materials it will use to accelerate the development of its hepatitis C rapid diagnostic test.
"It's one in a series of MTAs which will put us in the best possible position to have a rapid test that works with a number of rapid systems in the marketplace," said CEO Dr Martin Soust.
Soust said the agreement would cut at least three months off the timeframe required to develop the point-of-care test, and would allow the company to compare multiple rapid systems concurrently.
The MTA also contains the provision that the supplier company will be able to exercise rights to license or on-license any IP that arises from successful development.
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
